Tempus AI Receives EU Certification for xR RNA Sequencing

09:56 AM EDT, 10/26/2026 (MT Newswires) -- Tempus AI (TEM) said Monday its xR solid tumor profiling assay has received Class C certification under the European Union's In Vitro Diagnostic Regulation for cancer genomic profiling. The company said its assay detects gene rearrangements and splice variants in solid tumors. The certification supports EU access to xR beyond 2028 and its use in biopharma clinical studies, the company said. Tempus AI shares were down 3.2% in Monday trading. Price: 65.47, Change: -2.14, Percent Change: -3.17